No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration

Gynecological Endocrinology

Volumn 10, Issue 1, 1996, Pages 7-15

  Maraschini, C ^a   Moro, M ^a   Toja, P ^a   Braga, M ^b   Cavagnini, F ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Dopamine; Metoclopramide; Prolactin; Prolactinomas

Indexed keywords

DOPAMINE; METOCLOPRAMIDE; PROLACTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0030002039     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599609041264     Document Type: Article

References (30)

1. Serri, O., Kuchel, O., Buu, N. T. and Somma, M. (1983). Differential effect of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab., 56, 255-9
2. Spada, A., Nicosia, S., Cortellazzi, L., Pezzo, G., Bassetti, M., Sartorio, A. and Giannattasio, G. (1983). In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J. Clin. Endocrinol. Metab., 56, 1-10
3. Maraschini, C., Moro, M., Masala, A., Toja, P., Alagna, S., Brunani, A., Rovasio, P. P., Ginanni, A., Lancranjan, I. and Cavagnini, F. (1991). Chronic treatment with Parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol. (Copenh.), 125, 494-501
4. Koike, K., Miyake, A., Aono, T., Sakumoto, T., Ohmichi, M., Yamaguchi, M. and Tanizawa, O. (1991). Effect of prolactin on the secretion of hypothalamic GnRH and pituitary gonadotropins. Horm. Res., 35 (Suppl. 1), 5-12
5. Rodriguez-Arnao, M. D., Peters, J. R., Foord, S.M., Dieguez, C., Edwards, C., Gomez-Pan, A., Hall, R., Newcombe, R. G. and Scanlon, M. F. (1983). Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect. J. Clin. Endocrinol. Metab., 57, 975-80
6. Ghigo, E., Goffi, S., Molinatti, G. M., Camanni, F. and Massara, F. (1985). Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinemic women after dopamine synthesis blockade. Clin. Endocrinol., 23, 155-60
7. Kovacs, K., Ilse, G. and Ryan, M. (1980). Pituitary prolactin cell hyperplasia. Horm. Res., 12, 87-95
8. Sarkar, D. K., Gottschall, P. E. and Meites, J. (1984). Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology, 115, 1269-74
9. Paradisi, R., Grossi, G., Pintore, A., Venturoli, S., Porcu, E., Capelli, M. and Flamigni, C. (1991). Evidence for a pathological reduction in brain dopamine metabolism in idiopathic hyperprolactinemia. Acta Endocrinol. (Copenh.), 125, 246-52
10. Nicoletti, I., Filipponi, P., Fedeli, L., Ambrosi, F., Giammartino, C., Spinozzi, F. and Santeusanio, F. (1986). Catecholamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinemia. Acta Endocrinol. (Copenh.), 111, 154-61
11. Simpkins, J. W. and Gabriel, S. M. (1984). Chronic hyperprolactinemia causes progressive changes in hypothalamic dopaminergic and noradrenergic neurons. Brain Res., 309, 277-82
12. Bansal, S., Lee, L. A. and Woolf, P. D. (1981). Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. Am. J. Med., 71, 961-6
13. Tallo, D. and Malarkey, W. B. (1985). Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. Am. J. Obstet. Gynecol., 151, 651-5
14. Ho, K. Y., Smythe, G. A., Duncan, M. and Lazarus, L. (1984). Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism. J. Clin. Endocrinol. Metab., 58, 128-33
15. Connell, J. M. C., Padfield, P. L., Bunting, E. A., Ball, S. G., Inglis, G. C., Beastall, G. H., Teasdale, G. M. and Davies, D. L. (1983). Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinemia. Clin. Endocrinol., 18, 527-32
16. Ho, K. Y., Smythe, G. A. and Lazarus, L. (1986). Normal lactotroph sensitivity to graded low-dose dopamine infusion in pathological hyperprolactinemia. Neuroendocrinology, 43, 175-81
17. Bethea, C. L., Ramsdell, J. S., Jaffe, R. B., Wilson, C. B. and Weiner, R. I. (1982). Characterization of the dopaminergic regulation of human prolactin-secreting cells cultured on extracellular matrix. J. Clin. Endocrinol. Metab., 54, 893-902
18. Camanni, F., Genazzani, A. R., Massara, F., La Rosa, R., Cocchi, D. and Müller, E. E. (1980). Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology, 30, 2-6
19. Nicoletti, I., Ambrosi, F., Pagliacci, M. C., Pelicci, G., Giammartino, G., Maggio, D., Fedeli, L. and Filipponi, P. (1987). Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-mduced prolactin release in women with pathological hyperprolactinemia. Horm. Metab. Res., 19, 125-9
20. Quigley, M. E., Judd, S. J., Gilliland, G. B. and Yen, S. S. C. (1980). Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. J. Clin. Endocrinol. Metab., 50, 994-8
21. Müller, E. E., Cavagnini, F., Martinez-Campos, A., Maraschini, C., Giovannini, P., Novelli, A. and De Leo, V. (1984). Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders. Acta Endocrinol. (Copenh.), 107, 155-63
22. Del Pozo, E., Varga, L., Wyss, H., Tolis, G., Friesen, H., Wenner, R., Vetter, L. and Uettwiler, A. (1974). Clinical and hormonal response to bromocriptin (CB-154) in the galactorrhea syndrome. J. Clin. Endocrinol. Metab., 39, 18-26
23. Malarkey, W. (1975). Nonpuerperal lactation and normal prolactin regulation. J. Clin. Endocrinol. Metab., 40, 198-204
24. Healy, D. L., Pepperell, R. J., Stockdale, J., Bremner, W. J. and Burger, H. G. (1977). Pituitary autonomy in hyperprolactinemic secondary amenorrhea: results of hypothalamic-pituitary testing. J. Clin. Endocrinol. Metab., 44, 809-19
25. Nyboe Andersen, A., Hagen, C., Boesgaard, S., Eldrup, E. and Djursing, H. (1989). Possible thyrotrophs insensitivity to dopamine in hyperprolactinemic amenorrhoeic patients. Horm. Metab. Res., 21, 328-30
26. Ferrari, C., Rampini, P., Benco, R., Caldara, R., Scarduelli, C. and Crosignani, P. G. (1982). Functional characterization of hypothalamic hyperprolactinemia. J. Clin. Endocrinol. Metab., 55, 897-901
27. Erroi, A., Bassetti, M., Spada, A. and Giannattasio, G. (1986). Microvasculature of human micro- and macroprolactinomas. A morphological study. Neuroendocrinology, 43, 159-65
28. Schechter, J., Goldsmith, P., Wilson, C. and Weiner, R. (1988). Morphological evidence for the presence of arteries in human prolactinomas. J. Clin. Endocrinol. Metab., 67, 713-19
29. Gorczyca, W. and Hardy, J. (1988). Microadenomas of the human pituitary and their vascularization. Neurosurgery, 22, 1-6
30. Reichlin, S. and Molitch, M. (1984). Neuroendocrine aspects of pituitary adenoma. In Camanni, F. and Müller, E. E. (eds.) Pituitary hyperfunction, pp.47-52. (New York: Raven Press)